Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Abeona Therapeutics Inc. (ABEO : NSDQ)
 
 • Company Description   
Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

Number of Employees: 90

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.18 Daily Weekly Monthly
20 Day Moving Average: 2,011,185 shares
Shares Outstanding: 146.95 (millions)
Market Capitalization: $26.45 (millions)
Beta: 1.50
52 Week High: $1.92
52 Week Low: $0.13
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -32.81% -26.38%
12 Week -23.79% -17.31%
Year To Date -46.59% -36.48%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1330 AVENUE OF THE AMERICAS 33RD FLOOR
-
NEW YORK,NY 10019
USA
ph: 646-813-4701
fax: 214-905-5101
ir@abeonatherapeutics.com http://www.abeonatherapeutics.com
 
 • General Corporate Information   
Officers
Vishwas Seshadri - President; Chief Executive Officer
Michael Amoroso - Chairman of the Board
Joseph Vazzano - Chief Financial Officer
Edward Carr - Chief Accounting Officer
Christine Silverstein - Director

Peer Information
Abeona Therapeutics Inc. (CORR.)
Abeona Therapeutics Inc. (RSPI)
Abeona Therapeutics Inc. (CGXP)
Abeona Therapeutics Inc. (BGEN)
Abeona Therapeutics Inc. (GTBP)
Abeona Therapeutics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00289Y107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
Share - Related Items
Shares Outstanding: 146.95
Most Recent Split Date: 10.00 (0.02:1)
Beta: 1.50
Market Capitalization: $26.45 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.33 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.84
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 41.18%
vs. Previous Quarter: 28.57%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -88.47%
ROE
03/31/22 - -96.64
12/31/21 - -78.78
09/30/21 - -69.39
ROA
03/31/22 - -62.00
12/31/21 - -51.81
09/30/21 - -46.16
Current Ratio
03/31/22 - 3.18
12/31/21 - 3.33
09/30/21 - 2.57
Quick Ratio
03/31/22 - -
12/31/21 - 3.33
09/30/21 - 2.57
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -2,681.56
12/31/21 - -2,831.20
09/30/21 - -1,802.70
Book Value
03/31/22 - 0.21
12/31/21 - 0.35
09/30/21 - 0.79
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©